b
Alvotech and Stada debut uzpruvo, the first ustekinumab biosimilar in Europe
Alvotech and Stada launch Stelara biosimilar following European approval earlier this year and expiry of exclusivity rights on the original molecule.
Archives for July 24, 2024
Ensuring pharma data integrity: COPA-DATA’s automation solution tackles ALCOA challenges
Data integrity is a paramount concern for pharmaceutical manufacturers, particularly as they navigate the complexities of modern production with legacy equipment.
Global biosimilar market estimated to reach a size of $43.8 billion by the end of 2024
Demand for biosimilars is booming, with no hints of slowing down as the number of biosimilars getting approved keeps growing. Here are all the biosimilars that have received approval in 2024 to date.
FDA approves Samsung Bioepis’ Epsyqli biosimilar for PNH and aHUS treatment
Samsung Bioepis Co., Ltd. announced yesterday (July 23) that the US Food and Drug Administration (FDA) has approved Epsyqli (eculizumab-aagh) as a biosimilar to Soliris (eculizumab).
Boehringer Ingelheim and GoodRx undercut Humira by massive 92% with biosimilar
In a bid to make biologic treatments more accessible to patients, Boehringer Ingelheim is harnessing the reach and scale of the prescription savings platform GoodRx to provide its Humira biosimilar adalimumab-adbm at a low price.